Everest Organics

Which are the latest news on Everest Organics?

Why is Everest Organics Ltd falling/rising?

As of 05-Sep, Everest Organics Ltd's stock price is at 272.55, showing a slight increase today but a year-to-date decline of 46.12%. The stock is underperforming over longer periods and experiencing reduced investor participation, indicating potential weaknesses.

As of 05-Sep, Everest Organics Ltd's stock price is currently at 272.55, reflecting a slight increase of 0.65 (0.24%). Despite this small rise, the stock has shown a negative performance over various periods, with a year-to-date decline of 46.12% compared to a 10.21% drop in the benchmark Sensex. Over the past month, the stock has decreased by 9.07%, while the Sensex fell by only 2.44%. <BR><BR>Today, the stock has outperformed its sector by 0.71% and has experienced gains for the last two consecutive days, resulting in a total return of 2.08% during this period. However, it is important to note that Everest Organics is trading below its moving averages across all time frames, indicating a bearish trend. Additionally, there has been a decline in investor participation, with delivery volume dropping by 9.27% compared to the five-day average. <BR><BR>Overall, while there is a minor increase in the stock price today, the broader context shows significant declines over longer periods and a decrease in investor engagement, which may suggest underlying weaknesses in the stock's performance.

Who are in the management team of Everest Organics?

The management team of Everest Organics includes S K Hari Krishna (Whole-time Director), A Parvatisem (Director - Technical), K. Ramakrishnam Raju (Chairman & Independent Director), Raju S Kakarlapudi (Non-Executive Director), Srikakarlapudi Sirisha (Managing Director & CEO), Venkatasatyanarayana Murthy Chayaly (Independent Director), Abdur Rahman (Company Secretary & Compliance Officer), and SUNDARA PRASAD VENKATA SATYA SRIKAKOLAPU (Independent Director). They oversee the company's operations and strategic direction.

The management team of Everest Organics includes the following individuals:<BR><BR>1. **S K Hari Krishna** - Whole-time Director<BR>2. **A Parvatisem** - Director (Technical)<BR>3. **K. Ramakrishnam Raju** - Chairman & Independent Director<BR>4. **Raju S Kakarlapudi** - Non-Executive Director<BR>5. **Srikakarlapudi Sirisha** - Managing Director & CEO<BR>6. **Venkatasatyanarayana Murthy Chayaly** - Independent Director<BR>7. **Abdur Rahman** - Company Secretary & Compliance Officer<BR>8. **SUNDARA PRASAD VENKATA SATYA SRIKAKOLAPU** - Independent Director<BR><BR>This team is responsible for overseeing the operations and strategic direction of the company. If you have any more questions about Everest Organics or its management, feel free to ask!

What does Everest Organics do?

Everest Organics Ltd manufactures Active Pharmaceutical Ingredients and intermediaries in the Pharmaceuticals & Biotechnology industry. As of June 2026, it reported net sales of 48 Cr and a net profit of 1 Cr, with a market cap of INR 275 Cr.

Overview:<BR>Everest Organics Ltd is engaged in the manufacturing of Active Pharmaceutical Ingredients and their intermediaries, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap company.<BR><BR>History:<BR>Everest Organics Limited was incorporated in February 1993 in Hyderabad. The company commenced its commercial operations in the same year and reported net sales and profit for the quarter ending June 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 48 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: 1 Cr (Quarterly Results - Jun 2026)<BR>- Market Cap: INR 275 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 52.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.65<BR>- Return on Equity: 6.97%<BR>- Price to Book: 3.66<BR><BR>Contact Details:<BR>Address: Aroor Village, Sadasivpet Mandal Medak Telangana : 502291<BR>Tel: 91-8455-250113<BR>Email: srihari_everest@rediffmail.com<BR>Website: http://www.everestorganicsltd.com

Who are the peers of the Everest Organics?

Everest Organics' peers include Medicamen Biotec, Ambalal Sarabhai, Trident Lifeline, and others. Everest Organics has below-average growth and management risk, with a 1-year return of -30.60%, significantly lower than the highest peer return of 54.17% from BDH Industries.

Peers: The peers of Everest Organics are Medicamen Biotec, Ambalal Sarabhai, Trident Lifeline, Gennex Lab., BDH Industries, Astonea Labs, Zenotech Lab., Aarey Drugs, Lyka Labs, and Nectar Lifesci.<BR><BR>Quality Snapshot: Excellent management risk is observed at BDH Industries, while Average management risk is found at Medicamen Biotec, Trident Lifeline, Gennex Lab., Astonea Labs, Zenotech Lab., and Lyka Labs, and the rest. Below Average management risk is noted for Ambalal Sarabhai, Aarey Drugs, and Nectar Lifesci. Growth is Excellent at Trident Lifeline, Good at Gennex Lab. and Astonea Labs, Average at Medicamen Biotec, Zenotech Lab., and the rest, while Below Average growth is seen at Ambalal Sarabhai, Everest Organics, Aarey Drugs, Lyka Labs, and Nectar Lifesci. Capital Structure is Excellent at Gennex Lab. and BDH Industries, Good at Medicamen Biotec and Trident Lifeline, Average at Ambalal Sarabhai, and Below Average at Astonea Labs, Everest Organics, Aarey Drugs, Lyka Labs, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is BDH Industries at 54.17%, while Everest Organics has the lowest at -30.60%. This indicates that Everest Organics' 1-year return is significantly lower than that of BDH Industries. Additionally, the six-month return is negative for Everest Organics, Medicamen Biotec, and Zenotech Lab.

How big is Everest Organics?

As of 31st August, Everest Organics Ltd has a market capitalization of 275.00 Cr, with recent net sales of 190.77 Cr and a net profit of 5.26 Cr. Shareholder's funds are 69.95 Cr, and total assets amount to 224.48 Cr.

As of 31st August, Everest Organics Ltd has a market capitalization of 275.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Everest Organics reported Net Sales of 190.77 Cr and a Net Profit of 5.26 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 69.95 Cr and Total Assets of 224.48 Cr.

Should I buy, sell or hold Everest Organics Ltd?

Are Everest Organics Ltd latest results good or bad?

Everest Organics Ltd's latest results show a significant quarterly profit increase and improved operating margins, but year-on-year net profit has declined, and long-term growth remains stagnant with concerning financial health indicators. Overall, while there are positive short-term signs, the long-term outlook appears cautious due to persistent challenges.

The latest results for Everest Organics Ltd present a mixed picture. On one hand, the company reported a significant net profit of ₹2.63 crores for Q4 FY26, which is a remarkable increase of 630.56% compared to the previous quarter. This improvement in profitability is complemented by a strong operating margin of 13.74%, up from 8.31% in the prior quarter, indicating better cost management.<BR><BR>Additionally, revenue for the quarter grew by 14.46% quarter-on-quarter and 19.11% year-on-year, which suggests a positive trend in sales performance. However, despite these quarterly gains, the company faces serious challenges. Year-on-year, net profit has decreased by 9.62%, and the five-year sales growth rate is a mere 0.60%, indicating stagnation.<BR><BR>Moreover, the company has been experiencing declining operating profits over the past five years, with a compound annual contraction of 12.16%. The overall financial health is concerning, highlighted by a weak return on equity of 8.05% and a high debt-to-EBITDA ratio of 15.01 times, which suggests difficulties in managing debt obligations.<BR><BR>In summary, while the quarterly results show some positive indicators, the underlying long-term performance issues and financial challenges suggest that the overall outlook remains cautious. Investors may need to weigh the short-term gains against the persistent structural weaknesses in the business.

When is the next results date for Everest Organics Ltd?

The next results date for Everest Organics Ltd is 14 August 2026.

The next results date for Everest Organics Ltd is scheduled for 14 August 2026.

Is Everest Organics overvalued or undervalued?

As of December 4, 2025, Everest Organics is considered overvalued with a high PE ratio of 61.45 and other premium valuation metrics compared to its peers, indicating limited upside potential despite strong recent stock performance.

As of 4 December 2025, Everest Organics has moved from a fair to an expensive valuation grade. The company is currently considered overvalued based on its high PE ratio of 61.45, an EV to EBIT of 41.56, and a Price to Book Value of 5.61. These ratios indicate that the stock is trading at a premium compared to its earnings and book value, suggesting limited upside potential relative to its current price.<BR><BR>In comparison to its peers, Everest Organics' valuation stands out as significantly higher; for instance, Sun Pharma has a PE of 37.78 and an EV to EBITDA of 24.99, while Cipla, which is rated attractive, has a PE of 22.58 and an EV to EBITDA of 15.98. This stark contrast highlights Everest Organics' overvaluation in the context of the industry. Despite its strong recent stock performance, with a year-to-date return of 39.15% compared to the Sensex's 9.12%, the underlying valuation metrics suggest that investors may be overestimating the company's growth prospects.

How has been the historical performance of Everest Organics?

Everest Organics has experienced a decline in financial performance, with net sales dropping from 197.24 Cr in March 2024 to 159.48 Cr in March 2025, resulting in negative profits and cash flow challenges. The company's operating profit decreased significantly, reflecting volatility and reduced profitability in the latest fiscal year.

Answer:<BR>The historical performance of Everest Organics shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Everest Organics reported net sales of 159.48 Cr in March 2025, a decline from 197.24 Cr in March 2024 and 183.05 Cr in March 2023, indicating a downward trend in revenue. The total operating income mirrored this decline, falling to 159.48 Cr in March 2025 from 197.24 Cr in the previous year. Raw material costs decreased to 97.50 Cr in March 2025 from 123.41 Cr in March 2024, contributing to a total expenditure of 152.26 Cr, down from 186.25 Cr. Operating profit, excluding other income, was 7.22 Cr in March 2025, a decrease from 10.99 Cr in March 2024, leading to a profit before tax of -3.24 Cr in March 2025, compared to a profit of 0.61 Cr in March 2024. The profit after tax also turned negative at -1.29 Cr in March 2025, following a profit of 0.14 Cr in March 2024. The company's equity capital increased to 9.71 Cr in March 2025 from 8.00 Cr in March 2024, while total liabilities slightly decreased to 224.48 Cr from 226.62 Cr. Cash flow from operating activities was negative at -5.00 Cr in March 2025, contrasting with a positive cash flow of 16.00 Cr in March 2024, reflecting challenges in cash generation. Overall, the financial performance of Everest Organics indicates significant volatility and a decline in profitability in the most recent fiscal year.

Who are the top shareholders of the Everest Organics?

The top shareholders of Everest Organics include Veerat Finance Investment Limited with 38.37%, followed by Greenpath Energy Private Limited at 8.47%, and individual investors holding 23.87%. There are no pledged promoter holdings, mutual funds, or foreign institutional investors involved.

The top shareholders of Everest Organics include the promoters, with Veerat Finance Investment Limited holding the largest stake at 38.37%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Greenpath Energy Private Limited, which owns 8.47%. Additionally, individual investors collectively hold 23.87% of the shares.

What is the technical trend for Everest Organics?

As of April 3, 2025, Everest Organics shows a bullish trend supported by positive MACD and moving averages, but caution is advised due to bearish RSI readings indicating potential momentum weakness.

As of 3 April 2025, the technical trend for Everest Organics has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are both bullish, supporting the positive trend. Daily moving averages also indicate a bullish stance. However, the RSI readings are bearish on both weekly and monthly time frames, suggesting some weakness in momentum. The Bollinger Bands are mildly bullish on both time frames, indicating potential for upward movement. Overall, the current stance is bullish, but the bearish RSI signals indicate caution regarding the strength of this trend.

Has Everest Organics declared dividend?

Everest Organics Ltd has declared a 5% dividend, amounting to 0.5 per share, with an ex-date of September 15, 2022. Despite the dividend declaration, the yield remains at 0%, as the company's strong price returns have driven total returns across various periods.

Everest Organics Ltd has declared a 5% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 5%<BR>- Amount per share: 0.5<BR>- Ex-date: 15 Sep 22<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was 190.1%, with a dividend return of 0%, resulting in a total return of 190.1%.<BR><BR>For the 1-year period, the price return was 249.94%, with a dividend return of 0%, leading to a total return of 249.94%.<BR><BR>Over the 2-year period, the price return was 325.04%, and the dividend return was 0%, culminating in a total return of 325.04%.<BR><BR>In the 3-year period, the price return was 182.86%, with a dividend return of 0.38%, resulting in a total return of 183.24%.<BR><BR>For the 4-year period, the price return was 15.24%, with a dividend return of 0.44%, leading to a total return of 15.68%.<BR><BR>In the 5-year period, the price return was 223.93%, with a dividend return of 1.72%, culminating in a total return of 225.65%.<BR><BR>Overall, while Everest Organics has declared a dividend, the dividend yield remains at 0%, indicating that the dividends have not significantly contributed to the total returns. However, the company has shown strong price returns across all periods, suggesting robust performance in its stock value.